Literature DB >> 23974361

miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth.

Ning Wang, Qi Li, Ning-Han Feng, Gong Cheng, Zhao-Long Guan, Yang Wang, Chao Qin, Chang-Jun Yin, Li-Xin Hua.   

Abstract

The purpose of this study was to elucidate the molecular mechanisms of microRNA-205 (miR-205) as a tumor suppressor in prostate cancer (PCa). In the present study, microRNA microarray analysis suggested that the expression of miR-205 was significantly decreased in advanced PCa compared with early PCa. Real-time PCR analysis also indicated that miR-205 expression was significantly decreased in PCa tissues compared with non-cancerous tissues. Moreover, the expression of miR-205 has been demonstrated to be associated with the clinicopathological stage and total/free prostate-specific antigen (PSA) level of PCa. Functional analyses showed that both the overexpression of miR-205 and the knockdown of c-SRC in PCa cell lines could inhibit cell growth, colony formation, migration, invasion and the cell cycle as well as induce cell apoptosis in vitro. Furthermore, over-expressing miR-205 reduced tumorigenicity in vivo. Through a luciferase activity assay and Western blotting, c-SRC was identified as a target of miR-205 in cells. The overexpression of miR-205 suppressed c-SRC and its downstream signaling molecules, including FAK, p-FAK, ERK1/2 and p-ERK1/2, and attenuated cell proliferation, invasion and tumor growth.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23974361      PMCID: PMC3854052          DOI: 10.1038/aja.2013.80

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  41 in total

Review 1.  Proliferation, cell cycle and apoptosis in cancer.

Authors:  G I Evan; K H Vousden
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.

Authors:  Heike Aligayer; Douglas D Boyd; Markus M Heiss; Eddie K Abdalla; Steven A Curley; Gary E Gallick
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

Review 3.  beta-catenin signaling and cancer.

Authors:  P J Morin
Journal:  Bioessays       Date:  1999-12       Impact factor: 4.345

4.  Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue.

Authors:  D Reissig; J Clement; J Sänger; A Berndt; H Kosmehl; F D Böhmer
Journal:  J Cancer Res Clin Oncol       Date:  2001-04       Impact factor: 4.553

5.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

Review 6.  The hunting of the Src.

Authors:  G S Martin
Journal:  Nat Rev Mol Cell Biol       Date:  2001-06       Impact factor: 94.444

7.  MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer.

Authors:  Shahana Majid; Sharanjot Saini; Altaf A Dar; Hiroshi Hirata; Varahram Shahryari; Yuichiro Tanaka; Soichiro Yamamura; Koji Ueno; Mohd Saif Zaman; Kamaldeep Singh; Inik Chang; Guoren Deng; Rajvir Dahiya
Journal:  Cancer Res       Date:  2011-02-17       Impact factor: 12.701

8.  Src kinase contributes to the metastatic spread of carcinoma cells.

Authors:  Brigitte Boyer; Yveline Bourgeois; Marie-France Poupon
Journal:  Oncogene       Date:  2002-04-04       Impact factor: 9.867

Review 9.  Src in cancer: deregulation and consequences for cell behaviour.

Authors:  Margaret C Frame
Journal:  Biochim Biophys Acta       Date:  2002-06-21

10.  miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients.

Authors:  Z Hagman; B S Haflidadóttir; J A Ceder; O Larne; A Bjartell; H Lilja; A Edsjö; Y Ceder
Journal:  Br J Cancer       Date:  2013-04-09       Impact factor: 7.640

View more
  18 in total

Review 1.  The roles of microRNAs in the progression of castration-resistant prostate cancer.

Authors:  Satoko Kojima; Yusuke Goto; Yukio Naya
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

2.  MicroRNA-205 increases the sensitivity of docetaxel in breast cancer.

Authors:  Yang Cai; Xiang Yan; Guoqing Zhang; Weihong Zhao; Shunchang Jiao
Journal:  Oncol Lett       Date:  2015-12-11       Impact factor: 2.967

3.  MicroRNA (miR)-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma.

Authors:  J Cañueto; E Cardeñoso-Álvarez; J L García-Hernández; P Galindo-Villardón; P Vicente-Galindo; J L Vicente-Villardón; D Alonso-López; J De Las Rivas; J Valero; E Moyano-Sanz; E Fernández-López; J H Mao; A Castellanos-Martín; C Román-Curto; J Pérez-Losada
Journal:  Br J Dermatol       Date:  2017-05-08       Impact factor: 9.302

4.  MicroRNA-205 is downregulated in hepatocellular carcinoma and inhibits cell growth and metastasis via directly targeting vascular endothelial growth factor A.

Authors:  Xuya Zhao; Shi Zhou; Dazhi Wang; Wei He; Junxiang Li; Shuai Zhang
Journal:  Oncol Lett       Date:  2018-06-08       Impact factor: 2.967

5.  MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.

Authors:  Yang Wang; Ning Shao; Xueying Mao; Minmin Zhu; Weifei Fan; Zhixiang Shen; Rong Xiao; Chuncai Wang; Wenping Bao; Xinyu Xu; Chun Yang; Jian Dong; Deshui Yu; Yan Wu; Caixia Zhu; Liting Wen; Xiaojie Lu; Yong-Jie Lu; Ninghan Feng
Journal:  Oncotarget       Date:  2016-07-26

6.  Large oncosomes mediate intercellular transfer of functional microRNA.

Authors:  Matteo Morello; Valentina R Minciacchi; Paola de Candia; Julie Yang; Edwin Posadas; Hyung Kim; Duncan Griffiths; Neil Bhowmick; Leland W K Chung; Paolo Gandellini; Michael R Freeman; Francesca Demichelis; Dolores Di Vizio
Journal:  Cell Cycle       Date:  2013-09-23       Impact factor: 4.534

Review 7.  Noncoding RNAs as novel biomarkers in prostate cancer.

Authors:  C G H Rönnau; G W Verhaegh; M V Luna-Velez; J A Schalken
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

Review 8.  MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples.

Authors:  Alessio Cannistraci; Anna Laura Di Pace; Ruggero De Maria; Désirée Bonci
Journal:  Biomed Res Int       Date:  2014-09-16       Impact factor: 3.411

Review 9.  The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression.

Authors:  U-Ging Lo; Cheng-Fan Lee; Ming-Shyue Lee; Jer-Tsong Hsieh
Journal:  Int J Mol Sci       Date:  2017-09-30       Impact factor: 5.923

10.  The PCAT3/PCAT9-miR-203-SNAI2 axis functions as a key mediator for prostate tumor growth and progression.

Authors:  Fangfang Tao; Xinxin Tian; Zhiqian Zhang
Journal:  Oncotarget       Date:  2018-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.